Mineralys Therapeutics, Inc. Common Stock (MLYS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.36B
Last updated: Nov 17, 2026 at 11:06 AM ET
Mineralys Therapeutics, Inc. Common Stock (MLYS) Competitors
The companies most similar to Mineralys Therapeutics, Inc. Common Stock are Structure Therapeutics Inc. American Depositary Shares (GPCR), Tyra Biosciences (TYRA) and Ocular Therapeutix (OCUL). By market cap, Mineralys Therapeutics, Inc. Common Stock ranks 8th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B. The median P/E of the 3 companies with a P/E is 9.6x.
Peer Comparison
MLYS's ROIC of -51.1% is below the peer median of -40.9%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. Common Stock (MLYS) | $1.36B | N/A | N/A | 0.0% | -51.1% | 0.0% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tyra Biosciences Inc (TYRA) | $1.38B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ocular Therapeutix Inc (OCUL) | $1.37B | N/A | 26.9x | 0.0% | -52.1% | -11.5% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Tourmaline Bio Inc. (TRML) | $1.23B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Silence Therapeutics PLC (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| Harmony Biosciences Holdings (HRMY) | $1.98B | 9.6x | 1.9x | 18.0% | 13.7% | 12.3% | 0.00% |
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.55B | N/A | 59.3x | 0.0% | N/A | 0.0% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Monte Rosa Therapeutics Inc (GLUE) | $800.67M | N/A | 13.3x | -186.2% | N/A | 325.8% | 0.00% |
| Peer median | $1.37B | 9.6x | 15.0x | 0.0% | -40.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Mineralys Therapeutics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Tyra Biosciences Inc (TYRA) | Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes... | TYRA competitors |
| Ocular Therapeutix Inc (OCUL) | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development... | OCUL competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Tourmaline Bio Inc. (TRML) | Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions... | |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Silence Therapeutics PLC (SLN) | Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology... | SLN competitors |
| Harmony Biosciences Holdings (HRMY) | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. | HRMY competitors |
| Rapport Therapeutics, Inc. Common Stock (RAPP) | Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases... | RAPP competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Monte Rosa Therapeutics Inc (GLUE) | Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural... | GLUE competitors |
Frequently Asked Questions About MLYS
Who are Mineralys Therapeutics, Inc. Common Stock's main competitors?
The companies most similar to Mineralys Therapeutics, Inc. Common Stock include Structure Therapeutics Inc. American Depositary Shares (GPCR), Tyra Biosciences (TYRA), Ocular Therapeutix (OCUL), Inhibrx Biosciences (INBX) and Tourmaline Bio (TRML), listed from the closest match.
Who is Mineralys Therapeutics, Inc. Common Stock's biggest competitor?
Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Structure Therapeutics Inc. American Depositary Shares (GPCR) is the closest match by business profile, size, sector and industry.
How does MLYS stock compare with its competitors?
MLYS' net margin is 0.0% against a peer median of 0.0%.
Which of Mineralys Therapeutics, Inc. Common Stock's competitors pays a higher dividend?
Mineralys Therapeutics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Mineralys Therapeutics, Inc. Common Stock bigger than its competitors?
No. Mineralys Therapeutics, Inc. Common Stock is 8th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.
MLYS pages: Overview, Earnings, Forecast, Financials, Competitors